Multiple promising COVID-19 vaccines are under rapid development, with deployment of the initial supply expected by 2021. Careful design of a vaccine prioritization strategy across socio-demographic groups is an imminent and crucial public policy challenge given that (1) the eventual vaccine supply will be highly constrained for at least the first several months of the vaccination campaign, and (2) there are stark differences in transmission and severity of impacts from SARS-CoV-2 across groups. Previous experience with vaccine development mid-pandemic offers limited insights for SARS-CoV-2 prioritization: SARS and Zika vaccine development was incomplete when those outbreaks ended and the epidemiology of endemic human influenza viruses differ substantially from that of SARS-CoV-2. We assess the optimal allocation of a limited and dynamic COVID-19 vaccine supply in the U.S. across socio-demographic groups differentiated by age and essential worker status. The transmission dynamics are modeled using a compartmental (SEIR) model parameterized to capture our current understanding of the transmission and epidemiological characteristics of COVID-19, including key sources of group heterogeneity (susceptibility, severity, and contact rates). We investigate tradeoffs between three alternative policy objectives: minimizing infections, years of life lost, or deaths. Moreover, we model dynamic vaccine prioritization policies that respond to changes in the epidemiological status of the population as SARS-CoV-2 continues its march. Because contacts tend to be concentrated within age groups, there is diminishing marginal returns as vaccination coverage increases in a given group, increasing the group’s protective immunity against infection and mortality. We find that optimal prioritization consistently targets older essential workers. However, depending on the policy objective, younger essential workers are prioritized to minimize infections or seniors in order to minimize mortality. Optimal prioritization outperforms non-targeted vaccination strategies by up to 18% depending on the outcome optimized. For example, in our baseline model, cumulative mortality decreased on average by 17% (25,000 deaths in the U.S. population) over the course of the outbreak.
Optimal Dynamic Prioritization of Scarce COVID-19 Vaccines